Incannex Healthcare Plans to Redomicile to the US and List on the Nasdaq Global Market, Aims to Unlock Strategic Benefits Incannex Healthcare Limited

Incannex Healthcare Plans to Redomicile to the US and List on the Nasdaq Global Market, Aims to Unlock Strategic Benefits

Post image

Incannex Healthcare Limited (ASX: IHL), an Australian biopharmaceutical company specialising in the development of medical cannabis products and psychedelic therapies, has announced its intention to redomicile to the United States and list its shares on the Nasdaq Global Market, pending shareholder approval and regulatory requirements.

The proposed redomiciliation and listing by Incannex aim to provide several strategic advantages to the company. These benefits include access to a larger and more liquid capital market with a sophisticated understanding of medicinal cannabinoids, psychedelic therapies, and pharmaceutical development. Additionally, the move would enhance the company's visibility and profile among global investors, analysts, media outlets, and potential partners.

By redomiciling to the US, Incannex expects to improve its ability to attract and retain talent, particularly as most of its clinical trials are conducted in the country. The company anticipates a lower cost of equity and simplified corporate structure for any future potential merger or acquisition opportunities. The move would also align Incannex with its US biopharmaceutical peers, who typically trade at higher valuations compared to their Australian counterparts.

Story Continues.. after this ad because we need some dollarydoos





Incannex's planned initial public offering (IPO) will comprise American Depositary Shares (ADSs), with each ADS representing 50 ordinary Incannex shares. These ADSs will be listed on the Nasdaq. The company intends to call an extraordinary general meeting to seek shareholder approval for the issuance of shares under the offering.

The redomiciliation and listing process is expected to be completed by October 2023, subject to market conditions and regulatory approvals. Incannex will maintain its listing on the ASX until the redomiciliation is finalised, after which it will delist from the Australian stock exchange.

Joel Latham, CEO and Managing Director of Incannex Healthcare, described the proposed redomiciliation and listing as a "transformational milestone" for the company. Latham believes that the move will significantly enhance Incannex's ability to execute its growth strategy and deliver value to its shareholders.

Promote your business on our growing investor platform: Advertise With Us

Lykeshares 1y

#ASX:ASN Is Anson Resources’ US$330M Financing Deal the Key to Unlocking Utah’s Lithium Potential?

Is Anson Resources’ US$330M Financing Deal the Key to Unlocking Utah’s Lithium Potential?
Lykeshares 1y

#ASX:AZL Could the Dawson Bay Formation Unlock Arizona Lithium’s Full Potential?

Could the Dawson Bay Formation Unlock Arizona Lithium’s Full Potential?
Lykeshares 1y

#ASX:CXO Is Core Lithium’s Finniss Project Poised for a Long-Term Comeback?

Is Core Lithium’s Finniss Project Poised for a Long-Term Comeback?
Lykeshares 1y

#ASX:ENR Can Encounter Resources’ West Arunta Project Become Australia’s Next Major Niobium Discovery?

Can Encounter Resources’ West Arunta Project Become Australia’s Next Major Niobium Discovery?
Lykeshares 1y

#ASX:RDN Can Raiden’s Latest Hires Unlock the Full Potential of the Andover Complex?

Can Raiden’s Latest Hires Unlock the Full Potential of the Andover Complex?
Lykeshares 1y

#ASX:RDN Can Raiden’s New Drilling Program Unlock High-Grade Lithium at Andover South?

Can Raiden’s New Drilling Program Unlock High-Grade Lithium at Andover South?

Lykeshares 1y

#ASX:ASN How Will Anson Resources' Green River Lithium Project Shape the Future of Sustainable Mining?

How Will Anson Resources' Green River Lithium Project Shape the Future of Sustainable Mining?